SRR10842366
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- APOPTOSIS+0.400
- COMPLEMENT+0.400
- COAGULATION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- MYC_TARGETS_V2-0.400
- ADIPOGENESIS-0.300
- FATTY_ACID_METABOLISM-0.300
- MYC_TARGETS_V1-0.300
- PROTEIN_SECRETION-0.300
- BILE_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- DNA_REPAIR-0.200
- NOTCH_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4ff81b7f-2dbc-453f-a68b-fe40315b2ef7 | — | — | 0.916 |
| 2 | ea0e56e4-d9e3-44a2-9bdb-2e98554f6bff | — | — | 0.891 |
| 3 | SRR8518406 | — | D | 0.883 |
| 4 | SRR10842349 | — | — | 0.880 |
| 5 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.880 |
| 6 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.873 |
| 7 | TCGA-SY-A9G5-01A-11R-A38B-07 | — | — | 0.870 |
| 8 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.869 |
| 9 | BS_JBGZ7HHZ | ganglioneuroblastoma | — | 0.868 |
| 10 | s0122149 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |